"The voice for cancer physicians and their patients in Massachusetts."

FDA GRANTS ACCELERATED APPROVAL TO NIVOLUMAB (OPDIVO) FOR HCC PREVIOUSLY TREATED WITH SORAFENIB

25 Sep 2017 2:18 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo; Bristo-Myers Squibb) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software